Abstract
We studied the effect of early postoperative chemotherapy, including 5-fluorouracil (5-FU) for 5 days for patients with gastric cancer following noncurative resection. The study was prospectively randomised and controlled, and 162 (87. 1%) of 186 were eligible candidates for statistical assessment. Patients randomised to group A received therapy that is used widely to treat patients with gastric cancer in Japan; mitomycin C (MMC). OK-432. UFT and PSK. Patients randomised to group B received the same drugs given to group A plus 5-FU bolus injections for 5 days, beginning on postoperative day 2. There were no differences in prognostic factors and doses of the drugs prescribed, except for 5-FU. There was no difference in the toxicity rate between the groups. Generalised Wilcoxon test revealed a P value of 0. 169. and the 50% survival rate improved 1. 4-fold in patients with gastric cancer treated with early postoperative chemotherapy of MMC. OK-432 plus 5-FU injection.
| Original language | English |
|---|---|
| Pages (from-to) | 413-416 |
| Number of pages | 4 |
| Journal | British journal of cancer |
| Volume | 65 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1992 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer. / Maehara, Y.; Sugimachi, K.; Akagi, M.; Kakegawa, T.; Shimazu, H.; Tomita, M.
In: British journal of cancer, Vol. 65, No. 3, 03.1992, p. 413-416.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer
AU - Maehara, Y.
AU - Sugimachi, K.
AU - Akagi, M.
AU - Kakegawa, T.
AU - Shimazu, H.
AU - Tomita, M.
PY - 1992/3
Y1 - 1992/3
N2 - We studied the effect of early postoperative chemotherapy, including 5-fluorouracil (5-FU) for 5 days for patients with gastric cancer following noncurative resection. The study was prospectively randomised and controlled, and 162 (87. 1%) of 186 were eligible candidates for statistical assessment. Patients randomised to group A received therapy that is used widely to treat patients with gastric cancer in Japan; mitomycin C (MMC). OK-432. UFT and PSK. Patients randomised to group B received the same drugs given to group A plus 5-FU bolus injections for 5 days, beginning on postoperative day 2. There were no differences in prognostic factors and doses of the drugs prescribed, except for 5-FU. There was no difference in the toxicity rate between the groups. Generalised Wilcoxon test revealed a P value of 0. 169. and the 50% survival rate improved 1. 4-fold in patients with gastric cancer treated with early postoperative chemotherapy of MMC. OK-432 plus 5-FU injection.
AB - We studied the effect of early postoperative chemotherapy, including 5-fluorouracil (5-FU) for 5 days for patients with gastric cancer following noncurative resection. The study was prospectively randomised and controlled, and 162 (87. 1%) of 186 were eligible candidates for statistical assessment. Patients randomised to group A received therapy that is used widely to treat patients with gastric cancer in Japan; mitomycin C (MMC). OK-432. UFT and PSK. Patients randomised to group B received the same drugs given to group A plus 5-FU bolus injections for 5 days, beginning on postoperative day 2. There were no differences in prognostic factors and doses of the drugs prescribed, except for 5-FU. There was no difference in the toxicity rate between the groups. Generalised Wilcoxon test revealed a P value of 0. 169. and the 50% survival rate improved 1. 4-fold in patients with gastric cancer treated with early postoperative chemotherapy of MMC. OK-432 plus 5-FU injection.
UR - http://www.scopus.com/inward/record.url?scp=0026603810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026603810&partnerID=8YFLogxK
U2 - 10.1038/bjc.1992.84
DO - 10.1038/bjc.1992.84
M3 - Article
C2 - 1558796
AN - SCOPUS:0026603810
VL - 65
SP - 413
EP - 416
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 3
ER -